Mometasone furoate
Based on 4 publication(s) in Google Scholar
Mometasone furoate (Sch32088) is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic activity. Mometasone furoate acts as a corticosteroid agent and used for topical applications in chronic skin eczema and airway inflammation management of asthma in vivo
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 83919-23-7
- Formula: C27H30Cl2O6
- Molecular Weight:521.43
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Covalent Screening Library
HY-L036
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Nuclear Receptor Compound Library
HY-L126
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Toxicity Compound Library
HY-L155
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Animal Drug Library
HY-L218
Publications Citing Use of MedChemExpress (MCE) Mometasone furoate
More
Customer Validation & Images
-
IF
-
WB
-
WB
Biological Activity
IC50: Glucocorticoid Receptor
Mometasone furoate binds to a glucocorticoid receptor causes conformational changes in the receptor, separation from chaperones, and the receptor moves to the nucleus[1]. Mometasone furoate (0.1-10 μM; 2h before LPS stimulation) strongly inhibits LPS-stimulated nitrite production in a concentration-dependent manner in J774 macrophages, The IC50 value is 0.00024 μM for Mometasone furoate in J774 cells[1]. Mometasone furoate (0.1-10 μM; 2h before LPS stimulation) is more potent than DEX, it significantly inhibits iNOS expression at a 0.01 μM concentration whereas Dex became active at 0.1 μM. Additionally, the inhibition of cox-2 protein expression at 0.01 μM is 79% for Mometasone furoate and 39% for Dex[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 83919-23-7
-
Appearance Solid
-
Molecular Weight 521.43
-
Formula C27H30Cl2O6
-
Color White to off-white
-
SMILES
C[C@@]12[C@](C(CCl)=O)(OC(C3=CC=CO3)=O)[C@H](C)C[C@@]1([H])[C@]4([H])CCC5=CC(C=C[C@]5(C)[C@@]4(Cl)[C@@H](O)C2)=O
-
Synonyms
Sch32088
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
J Am Chem Soc
2021 Nov 10;143(44):18467-18480. PMID: 34648292 -
Hematology
Mometasone furoate inhibits growth of acute leukemia cells in childhood by regulating PI3K signaling pathway. [Abstract]2018 Sep;23(8):478-485. PMID: 29421985
Mometasone furoate purchased from MedChemExpress. Usage Cited in: Hematology. 2018 Sep;23(8):478-485. [Abstract]
MF (Mometasone furoate) inhibits CCRF-CEM cell invasion and migration. (The images represent that the invasive and migrated CCRF-CEM cells are stained by crystal violet.
Mometasone furoate purchased from MedChemExpress. Usage Cited in: Hematology. 2018 Sep;23(8):478-485. [Abstract]
MF (Mometasone furoate) induces CCRF-CEM cell apoptosis. Western blot analysis of CCRF-CEM cells treated with MF for 24 h.
Mometasone furoate purchased from MedChemExpress. Usage Cited in: Hematology. 2018 Sep;23(8):478-485. [Abstract]
Effects of MF (Mometasone furoate) on the PI3K signaling pathway in CCRF-CEM cells. Expression levels of AKT, p-AKT, mTOR, p-mTOR, p70S6K, Cyclin D1 and VEGF are measured in the CCRF-CEM cells treatment with MF using western blot analysis.
-
Am J Otolaryngol
2026 Jun 29;47(4):104878. PMID: 42413294 -
Solvent & Solubility
DMSO : 50 mg/mL (95.89 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9178 mL | 9.5890 mL | 19.1780 mL | 47.9451 mL |
| 5 mM | 0.3836 mL | 1.9178 mL | 3.8356 mL | 9.5890 mL | |
| 10 mM | 0.1918 mL | 0.9589 mL | 1.9178 mL | 4.7945 mL | |
| 15 mM | 0.1279 mL | 0.6393 mL | 1.2785 mL | 3.1963 mL | |
| 20 mM | 0.0959 mL | 0.4795 mL | 0.9589 mL | 2.3973 mL | |
| 25 mM | 0.0767 mL | 0.3836 mL | 0.7671 mL | 1.9178 mL | |
| 30 mM | 0.0639 mL | 0.3196 mL | 0.6393 mL | 1.5982 mL | |
| 40 mM | 0.0479 mL | 0.2397 mL | 0.4795 mL | 1.1986 mL | |
| 50 mM | 0.0384 mL | 0.1918 mL | 0.3836 mL | 0.9589 mL | |
| 60 mM | 0.0320 mL | 0.1598 mL | 0.3196 mL | 0.7991 mL | |
| 80 mM | 0.0240 mL | 0.1199 mL | 0.2397 mL | 0.5993 mL |
Mometasone furoate Related Classifications
HY-13693 Related Classifications
Powered by Bioz